May 08, 2014
BCC Research (www.bccresearch.com) reveals in its new report,JAK AND PI3K SIGNALING PATHWAY MARKETS, the global market for signal transduction therapies/inhibitors (JAK and PI3K) is expected to grow to $2.2 billion by 2018, with a five-year compound annual growth rate (CAGR) of 36.8%. Tofacitinib, the fastest growing segment, is expected to register a phenomenal CAGR of 70.9%
The commercialization of two JAK therapies/inhibitors—ruxolitinib (Jakafi) from Incyte Corp. for myelofibrosis and tofacitinib (Xeljanz) from Pfizer for rheumatoid arthritis—has provided a much-needed direction to develop target therapies for fatal diseases like cancer and inflammatory diseases.
Tofacitinib, far and away the dominant product in this market, was valued at $90.7 million in 2013 and is projected to reach $1.3 billion by 2018.
Meanwhile, ruxolitinib, which is moving at a significant 19.3% CAGR, is expected to reach $904.8 million in 2018.
“The growing market of therapies related to JAK and PI3K signal pathways have tremendous opportunity to grow since these therapies have the potential to target diseases like cancer and inflammatory diseases with no appropriate medications so far,” says BCC Research pharmaceutical analyst Shalini Shahani Dewan. “The current therapies are capable of reducing the disease burden but cannot cure. Furthermore, there is a growing patient base worldwide for cancers and inflammatory diseases.”
JAK AND PI3K SIGNALING PATHWAY MARKETS provides an overview of the global market for signal transduction therapies and inhibitors, including analyses of global market trends, with data from 2012 and 2013, and projections of CAGRs through 2018. It also presents information on approved products such as Ruxolitnib, as well as others in development. In addition, the study dicusses the regulatory environment which is impacting development, relevant patent analyses, and provides profiles of leading companies in the industry.
This report is intended for product developers/manufacturers/producers, multinationals, scientists, researchers, research universities, government and non-government organizations, and others interested in where this market is headed over the next five years.
Editors and reporters who wish to speak with the analyst, should contact Steven Cumming at email@example.com.
JAK and PI3K Signaling Pathway Markets( PHM168A )
Publish Date: Apr 2014
Data and analysis extracted from this press release must be accompanied by a statement identifying BCC Research LLC as the source and publisher. For media inquiries, email firstname.lastname@example.org or visit www.bccresearch.com/media to request access to our library of market research.